LH Sex- and Cycle-Related Differences: Normal Ranges, Optimal Values, and Clinical Interpretation

What Is LH and Why Does the Reference Range Vary So Much?

Luteinizing hormone is a glycoprotein released in pulses from the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) from the hypothalamus. Its job differs between sexes. In men, LH binds Leydig cells in the testes and drives testosterone synthesis. In women, LH triggers ovulation and supports the corpus luteum.

Because secretion is pulsatile and tightly regulated by sex steroids through feedback loops, a single serum LH value reflects a snapshot of a hormone that swings several-fold within hours. Reference ranges published by major laboratories, and endorsed by the Endocrine Society, are therefore always stratified by sex and, for women, by cycle phase. [1]

The Hypothalamic-Pituitary-Gonadal Axis in Brief

GnRH pulses leave the hypothalamus every 60 to 120 minutes. The pituitary responds with a burst of LH (and FSH). Gonadal steroids then feed back. Estradiol in women is unusual: it produces negative feedback at low concentrations but triggers a positive-feedback LH surge once estradiol surpasses roughly 200 pg/mL for at least 50 hours. [2] This surge is the event that produces ovulation.

Testosterone in men exerts predominantly negative feedback. When testosterone falls, LH rises to compensate. That compensatory rise is the distinguishing feature of primary hypogonadism.

Why LH Half-Life Matters for Timing Blood Draws

LH has a circulating half-life of approximately 20 minutes. A draw timed poorly relative to a pulse can place a result 30 to 50 percent below or above the mean. Averaging two or three samples drawn 30 minutes apart corrects for this. The Endocrine Society's 2018 testosterone guideline recommends the same strategy for testosterone, and the principle extends to LH interpretation when the clinical picture is uncertain. [3]

LH in Men: Reference Ranges and What Drives Variation

In reproductive-age men, most laboratories set the LH reference interval between 1.7 and 8.6 IU/L, though exact cut-points vary by assay platform. The Third National Health and Nutrition Examination Survey (NHANES III) reported a geometric mean LH of approximately 4.5 IU/L in healthy men aged 20 to 39. [4]

Testosterone Feedback Sets the Floor and Ceiling

Men with strong testosterone output suppress LH toward the lower third of the range. Men with naturally lower testosterone, but still within normal bounds, tend to run LH in the upper half. Neither pattern alone is pathological. The diagnostic information comes from pairing LH with total and free testosterone.

• High LH + low testosterone: consistent with primary hypogonadism (testicular failure), as seen in Klinefelter syndrome (47,XXY) or post-orchitis damage.
• Low or low-normal LH + low testosterone: consistent with secondary (central) hypogonadism, as seen in hyperprolactinemia, hemochromatosis, or exogenous androgen use. [5]
• High LH + normal testosterone: may signal early or compensated Leydig cell dysfunction, documented in aging men by the European Male Ageing Study (N=3,369). [6]

Age-Related Rise in LH

LH climbs gradually in men after age 40. The Massachusetts Male Aging Study found that LH increased roughly 1 to 2 percent per year in longitudinally followed men. [7] This reflects declining Leydig cell mass and reduced testosterone feedback inhibition. A man aged 65 with an LH of 9 IU/L and a low-normal testosterone sits in a biologically different category from a 30-year-old with the same LH, which is why age-stratified interpretation is clinically more precise than a single population-wide cutoff.

LH During and After Testosterone Replacement Therapy

Exogenous testosterone suppresses GnRH and LH through negative feedback, often driving LH below 0.1 IU/L within weeks. This suppression is the intended physiologic consequence of therapy but causes testicular atrophy and impairs spermatogenesis. Co-administration of human chorionic gonadotropin (hCG), which mimics LH at the LH receptor, preserves intratesticular testosterone and partial fertility potential during TRT. [8]

LH in Women: Phase-Specific Ranges Across the Menstrual Cycle

No single LH number describes a woman's normal state. The cycle produces four clinically distinct phases, each with its own reference interval.

Follicular Phase (Days 1 to 13 of a 28-Day Cycle)

LH stays relatively low and steady, averaging 3 to 6 IU/L in most assays, with a published range of 1.9 to 12.5 IU/L. FSH slightly exceeds LH early in this phase as it recruits follicles. A woman tested for fertility workup during the follicular phase and found to have LH of 14 IU/L should raise suspicion for polycystic ovary syndrome (PCOS), where tonic LH hypersecretion and an LH/FSH ratio above 2 or 3 is a recognized pattern, though it is not required for diagnosis under the Rotterdam criteria. [9]

The Midcycle LH Surge

The surge begins 24 to 36 hours before ovulation. Published peak values range from 8.7 to 76.3 IU/L depending on the assay and timing of the draw. An LH exceeding 25 IU/L in midcycle context is considered a positive ovulation signal by most urinary and serum-based ovulation predictor protocols. The World Health Organization reference preparation (WHO 2nd IRP 80/552) anchors LH assay calibration across commercial platforms. [10]

The surge lasts only 24 to 48 hours. A woman tested at the wrong time may have already cleared most of the peak. Serial daily testing from cycle day 10 onward captures the surge reliably.

Luteal Phase (Days 15 to 28)

After ovulation, LH drops sharply. The corpus luteum, now producing progesterone, maintains low LH through the remainder of the cycle. Values of 0.5 to 16.9 IU/L are within range. A persistently elevated LH in the luteal phase, combined with a progesterone below 3 ng/mL, suggests a luteal phase defect or absent ovulation.

Postmenopausal Women

Once ovarian estradiol production fails, LH rises substantially and stays elevated because the negative feedback signal is largely gone. Reference ranges in postmenopausal women (10.0 to 54.7 IU/L) overlap with midcycle surge values in younger women. This is why phase or menopausal status must always accompany any LH result. A postmenopausal woman with LH of 12 IU/L actually has a lower-than-expected value for her stage, which could indicate a pituitary or hypothalamic issue requiring further evaluation. [11]

What Is the Optimal LH Level?

"Optimal" is a narrower question than "normal." The reference range captures 95 percent of an apparently healthy population; the optimal range targets function.

Optimal LH for Male Fertility and Testosterone Production

Published fertility data and Leydig cell physiology converge on a target of approximately 3 to 9 IU/L in men actively trying to conceive or seeking peak testosterone output. Below 1.7 IU/L, spermatogenesis is almost always impaired. Above 9 IU/L in a reproductive-age man, compensation for testicular underperformance is already underway, and investigation of the cause is warranted rather than simply accepting the number as "still within range."

The Endocrine Society's 2018 Male Hypogonadism Guideline states: "We recommend measuring serum LH and FSH concentrations to distinguish between primary and secondary hypogonadism in men with consistently low testosterone." [3] A single LH value without a paired testosterone offers limited clinical information.

Optimal LH for Women Trying to Conceive

For ovulation to occur, the LH surge must reach a threshold amplitude (generally greater than 25 IU/L in serum) and last long enough to trigger follicle rupture. Women with anovulatory PCOS often show LH values chronically elevated to 10 to 15 IU/L without a discrete surge pattern, which is insufficient to drive ovulation despite not appearing flagrantly abnormal on a single draw.

A 2003 analysis published in Human Reproduction (N=696 cycles) found that cycles with an LH surge peak below 21 IU/L had significantly lower rates of confirmed ovulation by ultrasound compared to cycles with peaks above 40 IU/L. [12] This reinforces the importance of surge amplitude, not just presence.

LH Targets in Hypogonadotropic Hypogonadism Treatment

When pulsatile GnRH therapy or gonadotropin injections (LH plus FSH or hCG plus FSH) are used to induce fertility in men with secondary hypogonadism, achieving serum LH analogue activity sufficient to raise intratesticular testosterone is the goal. Trials of hCG monotherapy target a serum testosterone above 300 ng/dL as the functional endpoint, with LH often undetectable while hCG is active (hCG does not cross-react in standard LH immunoassays). [8]

Using LH to Distinguish Primary from Secondary Hypogonadism

This is the most clinically high-stakes application of LH measurement. The distinction determines treatment direction entirely.

Primary Hypogonadism

Primary hypogonadism means the gonads are failing to respond. Common causes in men include Klinefelter syndrome, mumps orchitis, radiation, and chemotherapy. In women, premature ovarian insufficiency (POI) is the primary hypogonadism equivalent, defined as loss of normal ovarian function before age 40.

LH and FSH rise because there is no steroid feedback to suppress the pituitary. FSH often rises disproportionately in POI, but LH is elevated as well. A 2019 European Society of Human Reproduction and Embryology (ESHRE) guideline on POI defines a confirmatory criterion as FSH above 25 IU/L on two occasions at least 4 weeks apart in a woman under 40. [13] LH accompanies that FSH elevation and supports the diagnosis.

Secondary (Central) Hypogonadism

Here the gonads are capable but the signal from above is absent or blunted. Causes include:

• Pituitary adenomas (particularly prolactinomas)
• Hemochromatosis with pituitary iron deposition
• Hypothalamic suppression from caloric restriction, excessive exercise, or opioid use
• Exogenous androgen or glucocorticoid excess

LH is low or inappropriately normal given the low steroid environment. A man with total testosterone of 180 ng/dL and an LH of 3.2 IU/L has a biochemically central pattern. Prolactin, iron studies, and MRI of the sella turcica are the next steps, not testosterone replacement alone. [5]

A Note on Overlap

Some men and women fall into a mixed picture, where partial gonadal failure coexists with mild central suppression. Obesity, for instance, aromatizes testosterone to estradiol, which suppresses LH centrally even as testicular function is modestly impaired. The European Male Ageing Study found that obesity was an independent predictor of lower LH for a given testosterone level, blunting the diagnostic signal of primary gonadal dysfunction in heavier men. [6]

LH and Polycystic Ovary Syndrome

PCOS, the most common endocrine disorder in reproductive-age women (affecting roughly 8 to 13 percent of women globally by WHO estimates [14]), shows a characteristic LH hypersecretion pattern. Increased GnRH pulse frequency preferentially drives LH over FSH, yielding the elevated LH/FSH ratio noted in early studies.

The Rotterdam consensus (2004) removed the LH/FSH ratio from formal diagnostic criteria because it lacks sufficient sensitivity and specificity when applied across populations. An LH/FSH ratio above 2 in a woman with oligomenorrhea and clinical or biochemical hyperandrogenism still strengthens a clinical PCOS diagnosis when the picture is ambiguous. [9]

Neuroendocrine studies using frequent blood sampling show LH pulse frequency as high as one per 40 minutes in women with PCOS, compared to roughly one per 90 minutes in normally cycling women. [15] This accelerated pulsatility is upstream of the LH elevation seen on standard serum testing.

LH Assay Considerations: Not All Tests Are Created Equal

Laboratories use different immunoassay platforms calibrated against different WHO reference preparations. LH values can differ by 15 to 30 percent between platforms measuring the same sample. The FDA 510(k) clearance process for LH assays does not require inter-assay harmonization to a single numeric target, which means switching laboratories mid-monitoring can introduce apparent changes that are assay artifacts, not biological ones.

The Endocrine Society and the American Association of Clinical Endocrinology (AACE) both recommend that serial LH monitoring in conditions like POI, fertility treatment, or hypogonadism follow-up use the same laboratory and same platform throughout the monitoring period. [3]

Hemolysis and lipemia can interfere with immunoassay signal. Biotin supplementation above 5 mg/day (a dose found in some over-the-counter hair and nail supplements) can cause false-low or false-high results depending on the assay architecture. The FDA issued a safety communication on biotin interference in 2019. [16] Patients should discontinue high-dose biotin at least 48 hours before any LH draw.

Special Populations: Transgender and Gender-Diverse Individuals

In transgender women (male sex assigned at birth) receiving gender-affirming hormone therapy, estradiol and antiandrogens suppress LH toward or below the lower limit of the female follicular phase range. A persistently elevated LH in this population may indicate insufficient estradiol levels for adequate gonadotropin suppression, and dose adjustment may be considered after clinical review.

In transgender men receiving testosterone, LH suppresses similarly to what is seen in cisgender men on TRT. If testosterone therapy is discontinued, LH recovery follows the same timeline as in cisgender individuals, typically 3 to 6 months for partial recovery, though data specific to transgender men are limited. [17]

Summary Reference Table: LH Ranges by Sex and Stage

| Population | Phase / Status | Typical Range (IU/L) | |---|---|---| | Men, age 20-39 | Steady-state | 1.7 to 8.6 | | Men, age 40-69 | Age-adjusted | 2.0 to 11.0 | | Women | Follicular | 1.9 to 12.5 | | Women | Midcycle surge | 8.7 to 76.3 | | Women | Luteal | 0.5 to 16.9 | | Women | Postmenopausal | 10.0 to 54.7 | | Men on TRT | Suppressed | <0.1 (expected) | | POI (women <40) | Confirmed elevated | >25 (repeated) |

Values are approximate and assay-dependent. Always interpret against the reference range provided by the performing laboratory.